- Home
- CRBP vs ENTX Comparison
CRBP vs ENTX Comparison
Compare CRBP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- ENTX
- Stock Information
- Founded
- CRBP 2009
- ENTX 2010
- Country
- CRBP United States
- ENTX Israel
- Employees
- CRBP N/A
- ENTX N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CRBP Health Care
- ENTX Health Care
- Exchange
- CRBP Nasdaq
- ENTX Nasdaq
- Market Cap
- CRBP 73.4M
- ENTX 69.6M
- IPO Year
- CRBP N/A
- ENTX 2018
- Fundamental
- Price
- CRBP $6.03
- ENTX $1.79
- Analyst Decision
- CRBP Strong Buy
- ENTX Strong Buy
- Analyst Count
- CRBP 10
- ENTX 1
- Target Price
- CRBP $60.89
- ENTX $10.00
- AVG Volume (30 Days)
- CRBP 207.2K
- ENTX 30.9K
- Earning Date
- CRBP 05-06-2025
- ENTX 05-09-2025
- Dividend Yield
- CRBP N/A
- ENTX N/A
- EPS Growth
- CRBP N/A
- ENTX N/A
- EPS
- CRBP N/A
- ENTX N/A
- Revenue
- CRBP N/A
- ENTX $181,000.00
- Revenue This Year
- CRBP N/A
- ENTX N/A
- Revenue Next Year
- CRBP $150.00
- ENTX N/A
- P/E Ratio
- CRBP N/A
- ENTX N/A
- Revenue Growth
- CRBP N/A
- ENTX N/A
- 52 Week Low
- CRBP $4.64
- ENTX $1.41
- 52 Week High
- CRBP $61.90
- ENTX $2.79
- Technical
- Relative Strength Index (RSI)
- CRBP 49.07
- ENTX 49.59
- Support Level
- CRBP $5.68
- ENTX $1.50
- Resistance Level
- CRBP $6.29
- ENTX $1.84
- Average True Range (ATR)
- CRBP 0.46
- ENTX 0.11
- MACD
- CRBP 0.19
- ENTX 0.03
- Stochastic Oscillator
- CRBP 84.24
- ENTX 85.50
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.